1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Japan Pharmaceuticals and Healthcare Report Q3 2016

Japan Pharmaceuticals and Healthcare Report Q3 2016

  • May 2016
  • -
  • Business Monitor International
  • -
  • 122 pages

Includes 3 FREE quarterly updates

BMI View: There will be opportunities for haemophilia products within the Japan pharmaceutical market.The country has the third largest population of haemophilia patients in Asia, high levels of adherence and anextensive health insurance coverage that significantly lowers financial barriers to high-value treatments.Correspondingly, these factors have seen high levels of company activity in Japan, which will demand thatfirms offer differentiated treatments to effectively compete in the country.

Headline Expenditure Projections

- Pharmaceuticals: JPY11.5trn (USD94.9bn) in 2015 to JPY11.7trn (USD101.6bn) by 2016 with a y-o-ygrowth of 2.2% in local currency terms and -7.1% in USD terms. Forecast unchanged from last quarter.

- Healthcare: JPY50trn (USD419bn) in 2015 to JPY51trn (USD461bn) in 2016 with a y-o-y growth of1.8% in local currency terms and 10% in USD terms. Forecast revised downwards due to new data fromthe World Health Organization. The US dollar amount remains volatile and will be contingent on theBank of Japan's decision to weaken the currency having recently implemented negative interest rates.

Table Of Contents

Japan Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Japan 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Japan 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Japan 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Japan 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Japan 2012-2020) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Japan 2012-2020) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Japan 2014-2020) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Japan 2014-2020) 30
Industry Risk Reward Index 31
Asia Pacific Risk/Reward Index - Q3 2016 31
Japan Risk/Reward Index 37
Rewards 37
Risks 37
Regulatory Review 39
Regulatory Development 39
Table: Re-examination Period 44
Pricing and Reimbursement 44
Table: Market Expansion Re-Pricing Formulas 46
Market Overview 47
Healthcare Sector 47
Table: Healthcare Resources (Japan 2010-2015) 48
Table: Healthcare Personnel (Japan 2010-2015) 49
Table: Healthcare Activity (Japan 2010-2015) 49
Research and Development 49
Clinical Trials 50
Epidemiology 51
Table: Estimated Number Of New Cases Of Cancer In Japan 53
Table: Japan: Dementia Cases And Types Across Different Areas 54
Competitive Landscape 56
Research-Based Industry 56
Table: Companies Represented By The JPMA 56
Table: Multinational Pharmaceutical Firm Activity 57
Generic Drug Industry 59
Table: Members Of The Japan Generic Medicines Association 60
Pharmaceutical Distribution 60
Pharmaceutical Retail Sector 62
Company Profile 63
Astellas 63
AstraZeneca 68
Daiichi Sankyo 71
Eisai 75
GlaxoSmithKline 81
Merck and Co 85
Mitsubishi Tanabe 88
Novartis 91
Pfizer 96
Sanofi 100
Sawai Pharmaceutical 103
Takeda Pharmaceutical Company 106
Demographic Forecast 111
Demographic Outlook 111
Table: Population Headline Indicators (Japan 1990-2025) 112
Table: Key Population Ratios (Japan 1990-2025) 112
Table: Urban/Rural Population and Life Expectancy (Japan 1990-2025) 113
Table: Population By Age Group (Japan 1990-2025) 113
Table: Population By Age Group % (Japan 1990-2025) 114
Glossary 116
Methodology 118
Pharmaceutical Expenditure Forecast Model 118
Healthcare Expenditure Forecast Model 118
Notes On Methodology 119
Risk/Reward Index Methodology 120
Index Overview 121
Table: Pharmaceutical Risk/Reward Index Indicators 121
Indicator Weightings 122

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.